ORGANIC
LETTERS
2010
Vol. 12, No. 17
3856-3859
Ruthenium-Catalyzed Aromatic C-H
Activation of Benzylic Alcohols via
Remote Electronic Activation
Andrew J. A. Watson,*,† Aoife C. Maxwell,‡ and Jonathan M. J. Williams†
Department of Chemistry, UniVersity of Bath, ClaVerton Down, Bath, BA2 7AY, U.K.,
and GlaxoSmithKline Research and DeVelopment, Gunnels Wood Road,
SteVenage, SG1 2NY, U.K.
Received July 6, 2010
ABSTRACT
Remote electronic activation of benzylic alcohols via temporary oxidation facilitates ruthenium-catalyzed arene C-H activation for a range of
aromatic alcohols.
Hydrogen transfer is a powerful tool for the oxidation of
alcohols and reduction of ketones. Several groups includ-
ing our own have used catalytic hydrogen transfer to
activate alcohols toward C-C1 and C-N2 bond formation,
as well as a range of oxidative transfomations.3 Typically,
this involves alcohol oxidation followed by interception
of the newly formed carbonyl with nucleophiles before
further transformation. However, it can be used to activate
functional groups electronically;4 for example, an allylic
alcohol can be oxidized to an R,ꢀ-unsaturated ketone
making the double bond far more susceptible to Michael
additions. This allows the manipulation of less reactive
functional groups by altering the electronics of the
substrate indirectly, also known as “remote electronic
activation”. In contrast, applications of catalytic arene
C-H activation with ruthenium by Murai5 and others6
have been mainly limited to electronically activated rings
via the use of carbonyls and nitriles.7 This provides an
opportunity to combine both methodologies, allowing
electronic activation of the aromatic ring toward C-H
activation via the oxidation of an alcohol by hydrogen
transfer (Scheme 1). The ruthenium complex needs to
perform three separate functions to achieve this process,
catalyzing: (i) alcohol oxidation by hydrogen transfer to
† University of Bath.
(5) (a) Murai, S.; Kakiuchi, F.; Sekine, S.; Tanaka, Y.; Kamatami, A.;
Sonoda, M.; Chatani, N. Nature 1993, 366, 529–531. (b) Kakiuchi, F.;
Yamamoto, Y.; Chatani, N.; Murai, S. Chem. Lett. 1995, 681–682. (c)
Kakiuchi, F.; Sato, T.; Igi, K.; Chatani, N.; Murai, S. Chem. Lett. 2001,
386–387. (d) Sonoda, M.; Kakiuchi, F.; Kamatani, A.; Chatani, N.; Murai,
S. Chem. Lett. 1996, 109–110. (e) Kakiuchi, F.; Tanaka, Y.; Sato, T.;
Chatani, N.; Murai, S. Chem. Lett. 1995, 679–680. Sato, T.; Kakiuchi, F.;
Chatani, N.; Murai, S. Chem. Lett. 1998, 893–894.
‡ GlaxoSmithKline Research and Development.
(1) (a) Hall, M. I.; Pridmore, S. J.; Williams, J. M. J. AdV. Synth. Catal.
2008, 350, 1975–1978. (b) Williams, V. M.; Leung, J. C.; Patman, R. L.;
Krische, M. J. Tetrahedron 2009, 65, 5024–5029. (c) Skucas, E.; Ngai,
M.-Y.; Komanduri, V.; Krische, M. J. Acc. Chem. Res. 2007, 40, 1394–
1401.
(2) (a) Blacker, A. J.; Farah, M. M.; Hall, M. I.; Marsden, S. P.; Saidi,
O.; Williams, J. M. J. Org. Lett. 2009, 11, 2039–2042. (b) Watson, A. J. A.;
Maxwell, A. C.; Williams, J. M. J. Org. Lett. 2009, 11, 2667–2670.
(3) Owston, N. A.; Parker, A. J.; Williams, J. M. J. Chem. Commun.
2008, 624–625.
(6) (a) Grigg, R.; Savic, V. Tetrahedron Lett. 1997, 38, 5737–5740. (b)
Martinez, R.; Simon, M.-O.; Chevalier, R.; Pautigny, C.; Genet, J.-P.;
Darses, S. J. Am. Chem. Soc. 2009, 131, 7887–7895. (c) Martinez, R.;
Simon, M.-O.; Chevalier, R.; Pautigny, C.; Genet, J.-P.; Darses, S. AdV.
Synth. Catal. 2009, 351, 153–157. (d) Bartoszewicz, A.; Mart´ın-Matute,
B. Org. Lett. 2009, 11, 1749–1752.
(4) (a) Black, P. J.; Edwards, M. G.; Williams, J. M. J. Tetrahedron
2005, 61, 1363–1374. (b) Edwards, M. G.; Williams, J. M. J. Angew. Chem.,
Int. Ed. 2002, 41, 4740–4743. (c) Cami-Kobeci, G.; Williams, J. M. J. Synlett
2003, 1, 124–126.
(7) Kakiuchi, F.; Sonoda, M.; Tsujimoto, T.; Chatani, N.; Murai, S.
Chem. Lett. 1999, 1083–1084.
10.1021/ol101548a 2010 American Chemical Society
Published on Web 08/09/2010